LEADER 04137nam  22006615  450 
001 9910300347103321
005 20200629193445.0
010   $a1-4939-0597-X
024 7 $a10.1007/978-1-4939-0597-3
035   $a(CKB)3710000000111794
035   $a(EBL)1730895
035   $a(OCoLC)884592855
035   $a(SSID)ssj0001243542
035   $a(PQKBManifestationID)11804512
035   $a(PQKBTitleCode)TC0001243542
035   $a(PQKBWorkID)11284633
035   $a(PQKB)10302120
035   $a(MiAaPQ)EBC1730895
035   $a(DE-He213)978-1-4939-0597-3
035   $a(PPN)178779202
035   $a(EXLCZ)993710000000111794
100   $a20140509d2014      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aHydroxychloroquine and Chloroquine Retinopathy /$fby David J. Browning
205   $a1st ed. 2014.
210  1$aNew York, NY :$cSpringer New York :$cImprint: Springer,$d2014.
215   $a1 online resource (303 p.)
300   $aDescription based upon print version of record.
311   $a1-322-03778-7 
311   $a1-4939-0596-1 
320   $aIncludes bibliographical references and index.
327   $a1. Preclinical Foundations: Relevant Anatomy and Physiology -- 2. Pharmacology of Chloroquine and Hydroxychloroquine -- 3. Toxicology of Hydroxychloroquine and Chloroquine and the Pathology of the Retinopathy They Cause -- 4. Definitions of Hydroxychloroquine and Chloroquine Retinopathy -- 5. Epidemiology of Hydroxychloroquine and Chloroquine Retinopathy -- 6. Natural History of Hydroxychloroquine and Chloroquine Retinopathy -- 7. Risk Factors for Hydroxychloroquine and Chloroquine Retinopathy -- 8. Ancillary Testing in Screening for Hydroxychloroquine and Chloroquine Retinopathy -- 9. Screening for Hydroxychloroquine and Chloroquine Retinopathy -- 10. Clinical Examples in Managing Patients Taking 4-Aminoquinolines.
330   $aMalpractice settlements are large for undetected hydroxychloroquine and chloroquine toxicity which, if untreated, can lead to permanent loss of central vision. Knowledge of the ocular toxicity of these drugs has increased during the past fifty years as their use has expanded. Hydroxychloroquine and Chloroquine Retinopathy is the first single-source book on the subject and is essential for the practicing ophthalmologists, rheumatologists, dermatologists, and internists who prescribe these drugs. It covers clinical topics such as signs and symptoms of toxicity, toxicity screening, ancillary testing, to whom and why the drugs are prescribed and dosing considerations. Additionally, the book addresses practice management considerations, including coding, reimbursement and equipment costs, and the medico-legal responsibilities of the rheumatologist and of the ophthalmologist. Guidelines for the management of hydroxychloroquine and chloroquine vary around the world and differences between the guidelines of the United Kingdom, the United States, and other countries are identified. The book concludes with a collection of case examples illustrating common clinical scenarios and their management. This book is a ?must-have? resource for physicians who use these drugs.
606   $aOphthalmology
606   $aRheumatology
606   $aDermatology
606   $aOphthalmology$3https://scigraph.springernature.com/ontologies/product-market-codes/H44004
606   $aRheumatology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33170
606   $aDermatology$3https://scigraph.springernature.com/ontologies/product-market-codes/H1900X
615  0$aOphthalmology.
615  0$aRheumatology.
615  0$aDermatology.
615 14$aOphthalmology.
615 24$aRheumatology.
615 24$aDermatology.
676   $a610
676   $a616.5
676   $a616.723061
676   $a616723
700   $aBrowning$b David J$4aut$4http://id.loc.gov/vocabulary/relators/aut$0755281
906   $aBOOK
912   $a9910300347103321
996   $aHydroxychloroquine and Chloroquine Retinopathy$91521744
997   $aUNINA